Site logo

Description

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for psychiatric disorders. The company advances mushroom-based psychedelic pharmaceuticals and non-psychedelic nutraceutical products for diverse markets as potential therapies for various psychiatric and neurological conditions.

Key Activities

Cybin has several drugs in their development pipeline, including CYB001 a psilocybin treatment for Major Depressive Disorder currently in Phase 2A/2B clinical trials. The company has also filed over 10 patents covering novel psychedelic compounds, delivery mechanisms, supportive treatment platforms, and a drug discovery pipeline of modified and novel tryptamines and phenethylamines. 

Company Status
Location